Insulet Corporation vs Johnson & Johnson
PODD vs JNJ — side-by-side comparison from reported financials. PODD leads 4, JNJ leads 5 of 9 comparable metrics.
Insulet Corporation
PODD · Healthcare
$135.28+0.60%Strong
Johnson & Johnson
JNJ · Healthcare
$261.79+2.07%Mixed
| Metric | PODD | JNJ |
|---|---|---|
| Price | $135.28 | $261.79 |
| Market cap | $9.38B | $631B |
| Revenue (TTM) | $3.05B | $97.9B |
| Revenue growth | +27.5% | +5.6% |
| Net margin | 12.3% | 21.5% |
| Free cash flow | $294M | $22.2B |
| Net cash (debt) | ($215M) | ($27.8B) |
| 1-year price return | -57.8% | +37.0% |
| P/E | 25.0 | 29.9 |
| P/E vs own history (cheap-side %) | 99% | 16% |
| Dividend yield | — | 2.00% |
| Return on equity | 17% | 26% |
| Altman Z-score | 4.61 | — |
| CV checks passed | 10 of 10 | 10 of 10 |
| Employees | 5,400 | 140,800 |
Full résumé-style profiles: PODD CV · JNJ CV
Green marks the stronger side on comparable metrics. Figures are derived from company filings and may be delayed, restated or incomplete — information, not investment advice.